Alexion Pharmaceuticals Given New $200.00 Price Target at Leerink Swann (ALXN)
Equities research analysts at Leerink Swann boosted their target price on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $125.00 to $200.00 in a research note issued to investors on Friday, Stock Ratings News reports. Leerink Swann’s target price suggests a potential upside of 26.00% from the stock’s previous close.
A number of other firms have also recently commented on ALXN. Analysts at Canaccord Genuity raised their price target on shares of Alexion Pharmaceuticals from $161.00 to $200.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Barclays raised their price target on shares of Alexion Pharmaceuticals from $141.00 to $181.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Alexion Pharmaceuticals from $138.00 to $207.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $149.28.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 2.02% during mid-day trading on Friday, hitting $158.73. The stock had a trading volume of 3,063,832 shares. Alexion Pharmaceuticals has a one year low of $81.82 and a one year high of $169.98. The stock’s 50-day moving average is $134.5 and its 200-day moving average is $119.3. The company has a market cap of $31.123 billion and a price-to-earnings ratio of 91.63.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. Analysts expect that Alexion Pharmaceuticals will post $3.60 EPS for the current fiscal year.
In other Alexion Pharmaceuticals news, EVP Stephen P. Squinto unloaded 1,118 shares of Alexion Pharmaceuticals stock on the open market in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $133.31, for a total value of $149,040.58. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.